National Cancer Institute; Notice of Meetings, 23815-23816 [2017-10549]
Download as PDF
<![CDATA[
23815
Federal Register / Vol. 82, No. 99 / Wednesday, May 24, 2017 / Notices
ACL estimates the burden hours for
this collection of information as follows:
Number of
respondents
Number of
responses
per
respondent
Average
burden hours
per
response
Total burden
hours
New Grantees ..................................................................................................
Continuations and Final Reports .....................................................................
75
200
1
1
52
22
3,900
4,400
Total ..........................................................................................................
........................
........................
........................
8,300
Dated: May 18, 2017.
Daniel P. Berger,
Acting Administrator and Assistant Secretary
for Aging.
[FR Doc. 2017–10634 Filed 5–23–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meetings
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; Mentored Career
Development (K) and Conference (R13)
Award Application Review 2017–10.
Date: June 19, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John P Holden, Ph.D.,
Scientific Review Officer, National Institute
of Health, National Institute of Biomedical
Imaging and Bioengineering, Bethesda, MD
20892, (301) 496–8947, john.holden@nih.gov.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; Quantum Review
Meeting (2017/01).
Date: June 28, 2017.
Time: 09:00 a.m. to 6:00 p.m.
VerDate Sep<11>2014
19:43 May 23, 2017
Jkt 241001
Agenda: To review and evaluate grant
applications.
Place: Crystal Gateway Marriott, 1700
Jefferson Davis Highway, Arlington, VA
22202.
Contact Person: Dennis Hlasta, Ph.D.,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
National Institutes of Health, 6707
Democracy Blvd., Bethesda, MD 20892, (301)
451–4794, dennis.hlasta@nih.gov.
Dated: May 18, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10550 Filed 5–23–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App. 2), notice is
hereby given of the joint meeting of the
National Cancer Advisory Board
(NCAB) and NCI Board of Scientific
Advisors (BSA).
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board Ad Hoc Subcommittee on
Cancer Centers.
Open: June 19, 2017, 5:30 p.m. to 7:00 p.m.
Agenda: Discussion on Cancer Centers.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, Maryland 20814.
Contact Person: Dr. Henry P. Ciolino,
Executive Secretary, NCAB Ad Hoc
Subcommittee on Cancer Centers, National
Cancer Institute—Shady Grove, National
Institutes of Health, 9609 Medical Center
Drive, Room 2W102, Bethesda, MD 20892,
(240) 276–5624, henry.ciolino@nih.gov.
Name of Committee: National Cancer
Advisory Board Ad Hoc Subcommittee on
Population Science, Epidemiology and
Disparities.
Open: June 19, 2017, 7:30 p.m. to 9:00 p.m.
Agenda: Discussion on Population Science,
Epidemiology and Disparities.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, Maryland 20814.
Contact Person: Dr. Deborah Winn,
Executive Secretary, NCAB Ad Hoc
Subcommittee on Population Science,
Epidemiology and Disparities, National
Cancer Institute—Shady Grove, National
Institutes of Health, 9609 Medical Center
Drive, Room 4E344, Bethesda, MD 20892,
(240) 276–6755, winnde@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Open: June 20, 2017, 8:00 a.m. to 4:30 p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors; NCI Board of Scientific
Advisors Concepts Review, NCI Acting
Director’s report.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, Room 7W444, Bethesda, MD
20892, 240–276–6340, grayp@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board.
Closed: June 20, 2017, 4:45 p.m. to 5:30
p.m.
Agenda: Review of NCAB grant
applications.
E:\FR\FM\24MYN1.SGM
24MYN1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
23816
Federal Register / Vol. 82, No. 99 / Wednesday, May 24, 2017 / Notices
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, Room 7W444, Bethesda, MD
20892, 240–276–6340, grayp@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Open: June 21, 2017, 8:00 a.m. to 12:00
p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors; NCI Board of Scientific
Advisors Concepts Review.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, Room 7W444, Bethesda, MD
20892, 240–276–6340, grayp@mail.nih.gov.
Name of Committee: NCI Board of
Scientific Advisors Ad Hoc Subcommittee on
HIV and AIDS Malignancy.
Open: June 21, 2016, 1:00 p.m. to 5:00 p.m.
Agenda: Discussion on HIV and AIDS
Malignancy.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Dr. Robert Yarchoan,
Executive Secretary, NCI Board of Scientific
Advisors Ad Hoc Subcommittee on HIV and
AIDS Malignancy, National Cancer Institute,
National Institutes of Health, 10 Center Drive,
Building 10, Room 6N106, Bethesda, MD
20892, (301) 496–0328, robert.yarchoan@
nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: NCAB: https://
deainfo.nci.nih.gov/advisory/ncab/ncab.htm,
BSA: https://deainfo.nci.nih.gov/advisory/
bsa/bsa.htm, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
VerDate Sep<11>2014
19:43 May 23, 2017
Jkt 241001
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 18, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10549 Filed 5–23–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Call for Nominations for the NonFederal Members of the
Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC)
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Secretary of Health and
Human Services, in accordance with the
21st Century Cures Act, is seeking
nominations for the non-federal
members of the ISMICC.
FOR FURTHER INFORMATION CONTACT:
Pamela Foote, Substance Abuse and
Mental Health Services Administration,
5600 Fishers Lane, 14E53C, Rockville,
MD 20857; telephone: 240–276–1279;
email: pamela.foote@samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background and Authority
The ISMICC is established in
accordance with section 6031 of the 21st
Century Cures Act, and the Federal
Advisory Committee Act, 5 U.S.C. App.,
as amended, to report to the Secretary,
Congress, and any other relevant federal
department or agency on advances in
serious mental illness (SMI) and serious
emotional disturbance (SED), research
related to the prevention of, diagnosis
of, intervention in, and treatment and
recovery of SMI, SED, and advances in
access to services and support for adults
with SMI or children with SED. In
addition, the ISMICC will evaluate the
effect that federal programs related to
serious mental illness have on public
health, including public health
outcomes such as (A) rates of suicide,
suicide attempts, incidence and
prevalence of SMIs, SEDs, and
substance use disorders, overdose,
overdose deaths, emergency
hospitalizations, emergency room
boarding, preventable emergency room
visits, interaction with the criminal
justice system, homelessness, and
unemployment; (B) increased rates of
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
employment and enrollment in
educational and vocational programs;
(C) quality of mental and substance use
disorders treatment services; or (D) any
other criteria as may be determined by
the Secretary. Finally, the ISMICC will
make specific recommendations for
actions that agencies can take to better
coordinate the administration of mental
health services for adults with SMI or
children with SED. Not later than 1
(one) year after the date of enactment of
the 21st Century Cures Act, and 5 (five)
years after such date of enactment, the
ISMICC shall submit a report to
Congress and any other relevant federal
department or agency.
II. Committee Composition
The ISMICC will consist of federal
members listed below or their designees
and non-federal public members.
Federal Membership: The ISMICC
will be composed of the following
federal members or their designees:
• The Secretary of Health and Human
Services;
• The Assistant Secretary for Mental
Health and Substance Use;
• The Attorney General;
• The Secretary of the Department of
Veterans Affairs;
• The Secretary of the Department of
Defense;
• The Secretary of the Department of
Housing and Urban Development;
• The Secretary of the Department of
Education;
• The Secretary of the Department of
Labor;
• The Administrator of the Centers
for Medicare and Medicaid Services;
and
• The Commissioner of the Social
Security Administration.
In accordance with the Committee’s
authorizing statute, the Committee shall
also ‘‘include not less than 14 nonFederal public members appointed by
the Secretary of Health and Human
Services.’’ 21st Century Cures Act,
section 6031(e)(2).
All non-Federal public members are
appointed as Special Government
Employees for their service on the
ISMICC, of which:
(A) At least 2 members shall be an
individual who has received treatment
for a diagnosis of a serious mental
illness;
(B) At least 1 member shall be a
parent or legal guardian of an adult with
a history of a serious mental illness or
a child with a history of a serious
emotional disturbance;
(C) At least 1 member shall be a
representative of a leading research,
advocacy, or service organization for
adults with a serious mental illness;
E:\FR\FM\24MYN1.SGM
24MYN1
]]>Agencies
[Federal Register Volume 82, Number 99 (Wednesday, May 24, 2017)]
[Notices]
[Pages 23815-23816]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10549]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App. 2), notice is hereby given of the joint meeting
of the National Cancer Advisory Board (NCAB) and NCI Board of
Scientific Advisors (BSA).
The meetings will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting. The open session will be
videocast and can be accessed from the NIH Videocasting and Podcasting
Web site (https://videocast.nih.gov).
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board Ad Hoc
Subcommittee on Cancer Centers.
Open: June 19, 2017, 5:30 p.m. to 7:00 p.m.
Agenda: Discussion on Cancer Centers.
Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda,
Maryland 20814.
Contact Person: Dr. Henry P. Ciolino, Executive Secretary, NCAB
Ad Hoc Subcommittee on Cancer Centers, National Cancer Institute--
Shady Grove, National Institutes of Health, 9609 Medical Center
Drive, Room 2W102, Bethesda, MD 20892, (240) 276-5624,
henry.ciolino@nih.gov.
Name of Committee: National Cancer Advisory Board Ad Hoc
Subcommittee on Population Science, Epidemiology and Disparities.
Open: June 19, 2017, 7:30 p.m. to 9:00 p.m.
Agenda: Discussion on Population Science, Epidemiology and
Disparities.
Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda,
Maryland 20814.
Contact Person: Dr. Deborah Winn, Executive Secretary, NCAB Ad
Hoc Subcommittee on Population Science, Epidemiology and
Disparities, National Cancer Institute--Shady Grove, National
Institutes of Health, 9609 Medical Center Drive, Room 4E344,
Bethesda, MD 20892, (240) 276-6755, winnde@mail.nih.gov.
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Open: June 20, 2017, 8:00 a.m. to 4:30 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors; NCI Board of Scientific Advisors
Concepts Review, NCI Acting Director's report.
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, Room
7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.
Name of Committee: National Cancer Advisory Board.
Closed: June 20, 2017, 4:45 p.m. to 5:30 p.m.
Agenda: Review of NCAB grant applications.
[[Page 23816]]
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, Room
7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Open: June 21, 2017, 8:00 a.m. to 12:00 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors; NCI Board of Scientific Advisors
Concepts Review.
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, Room
7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.
Name of Committee: NCI Board of Scientific Advisors Ad Hoc
Subcommittee on HIV and AIDS Malignancy.
Open: June 21, 2016, 1:00 p.m. to 5:00 p.m.
Agenda: Discussion on HIV and AIDS Malignancy.
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Dr. Robert Yarchoan, Executive Secretary, NCI
Board of Scientific Advisors Ad Hoc Subcommittee on HIV and AIDS
Malignancy, National Cancer Institute, National Institutes of
Health, 10 Center Drive, Building 10, Room 6N106, Bethesda, MD
20892, (301) 496-0328, robert.yarchoan@nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm, BSA:
https://deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: May 18, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-10549 Filed 5-23-17; 8:45 am]
BILLING CODE 4140-01-P
